IDEX (IEX) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
23 Mar, 2026Strategic positioning and business model
Focuses on mission-critical engineered products, pivoting toward higher-growth, specialized markets with proprietary technologies across diverse sectors.
Operates under the 8020 model, emphasizing simplification, agility, and autonomy to drive growth and execution.
Maintains a global presence, serving customers in over 100 countries with approximately 8,700 employees.
Asset-light manufacturing model with high-margin, differentiated technology and long-term customer relationships.
Value drivers and growth strategy
Continuously evolves its portfolio toward high-growth markets with secular tailwinds, leveraging disciplined capital allocation.
Pursues above-market organic growth and margins, amplified by strategic M&A and portfolio optimization.
Targets compounding double-digit EPS growth over the long term.
Balances capital deployment between bolt-on acquisitions, dividends, and share repurchases, with a $1B repurchase authorization.
Segment and market focus
Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products are the main segments, contributing 43%, 35%, and 22% of 2025 net sales, respectively.
Targets advantaged markets such as data centers, space and defense, semiconductors, and water, supported by recent acquisitions.
Integrated platforms in materials science and life sciences drive innovation and cross-business synergies.
Latest events from IDEX
- 8020 model and strategic acquisitions fuel growth in high-margin, specialized markets.IEX
Investor presentation5 Mar 2026 - Midpoint of phase three: HST drives growth, digital and AI adoption accelerate, M&A continues.IEX
Citi's Global Industrial Tech & Mobility Conference 202617 Feb 2026 - Record HST-driven growth and margin gains support 2026 outlook amid industrial headwinds.IEX
Q4 20254 Feb 2026 - $1B acquisition expands tech capabilities and market reach, with strong synergy and margin upside.IEX
M&A Announcement3 Feb 2026 - Q2 sales fell 5%, margins and EPS improved, guidance cut, and $1B Mott deal announced.IEX
Q2 20242 Feb 2026 - Q3 sales up 1%, adjusted EPS down 10%, Mott deal closed, and guidance steady amid macro risks.IEX
Q3 202417 Jan 2026 - Record Q4 sales and margin gains set up 2025 for organic growth and EPS expansion.IEX
Q4 20249 Jan 2026 - Record orders and resilient margins offset organic sales and EPS declines in Q1.IEX
Q1 202525 Dec 2025 - Board recommends all proposals except the shareholder hiring report, emphasizing governance and ESG.IEX
Proxy Filing15 Dec 2025